At SkylineDx, we’re on a mission to transform healthcare by offering scientifically robust and clinically relevant molecular diagnostic tests that address a current unmet medical need.
Whether it regards diagnosing faster, deselecting patients for procedures, or finding therapy responders, our tests support care providers and patients in their treatment decision-making. Each test delves into the biology of the disease and analyses a patient’s unique gene expression, unraveling their individual disease profile and empowering those involved to make informed choices at pivotal moments in their lives.
We LIVE to make a difference
Our innovative medical technology is already making a significant impact. Our team is driven by scientific research, data science, and clinical relevance. It is not a solo journey. While we are disease agnostic, we pride ourselves in having a very clear focus: bridging the gap between (academically) discovered biomarkers and commercially available diagnostic assays. This means we collaborate with esteemed medical (academic) centers in the United States and Europe to further develop their foundational and instrumental work in biomarker discovery. Once launched commercially, we sign commercial partnerships to strengthen the sales and marketing efforts, expanding the test’s footprint globally.
Value-based healthcare starts with comprehensive molecular diagnostics that address a clinical unmet need. In collaboration with our partners, we are dedicated to making these tests available in the real-world setting through a focus on reimbursement and market access for patients.
Before a new molecular biomarker enters our Research & Development Programs, all discoveries and research opportunities are thoroughly evaluated in our dedicated STRIX (Systematic, Translational R&D Workflow, building on Integrated Expertise) Program. Our interdisciplinary team searches, screens, and evaluates hundreds of high-potential biomarkers a year, selecting the most promising. We then partner with the inventor and potentially license the related intellectual property (IP) that allows us to develop and commercialize the biomarker.
We form strong partnerships with technology transfer offices from hospitals and academia, as well as close collaboration with the involved clinicians and researchers directly. When a biomarker progresses from STRIX to one of our R&D Programs, we might file and develop additional IP.
Strix is a genus of the owl family and symbolizes wisdom and perception. Its sharp perception of details, broad view, and ability to see in the dark closely resembles what the STRIX Program is capable of making visible which would otherwise remain hidden.
Melanoma is an aggressive type of skin cancer. In melanoma, we have an extensive collaboration named the Falcon R&D Program. As the falcon bird is known as an intelligent creature with unprecedented senses and skills, our R&D program is uniquely equipped to unveil new, detailed insights in the genomic, biologic and clinical nature of melanoma.Â
Under the wings of the Falcon R&D Program, a series of specific studies and projects has been initiated, aimed at developing and introducing an array of diagnostic utilities, to provide physicians with the tools to optimize the clinical pathway of their patients. Not by coincidence, related series of studies are named after birds of prey in the Falcon family.
The Panthera Program focuses on hematological malignancies, cancers that develop in blood cells. Tackling hematological cancer requires strength and intelligence. Conditions such as multiple myeloma hide deep in the bone marrow.
Infectious and Inflammatory diseases consist of many disorders and studies suggest that a dysfunction of the immune system seems to be an important shared characteristic. The first disease in this program is Kawasaki disease.
At the core, our greatest asset is our people. From visionary leaders to talented scientists and dedicated staff. Each member of the SkylineDx team is united by a shared commitment to make a difference. Our teams are structured to advance the research and development in 3 dedicated programs, personified by animal genera: Falcon R&D Program for Dermato-Oncology, Panthera R&D Program for hematology and Delphia R&D Program for infectious & inflammatory diseases.
What others have to say about us
SkylineDx is ISO 13485:2016 certified
